BK-020 (VEGF Inhibitor Biosimilar)
Colorectal Cancer, NSCLC, Age-related Macular Degeneration
LaunchedMarketed
Key Facts
Indication
Colorectal Cancer, NSCLC, Age-related Macular Degeneration
Phase
Launched
Status
Marketed
About Sichuan Biokin Pharmaceutical
Sichuan Biokin Pharmaceutical's mission is to develop and commercialize high-quality, accessible biologic medicines for patients in China and worldwide. The company has achieved significant success by establishing itself as a dominant player in the Chinese biologics market, evidenced by its substantial market capitalization and integrated capabilities from discovery through commercialization. Its core strategy employs a dual-track approach: generating stable cash flow from biosimilars to fund the research and development of novel therapeutic antibodies in high-value therapeutic areas.
View full company profile